Skip Navigation


Brain Advance Access originally published online on April 27, 2005
Brain 2005 128(8):1841-1846; doi:10.1093/brain/awh520
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
128/8/1841    most recent
awh520v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kiernan, M. C.
Right arrow Articles by Berkovic, S. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kiernan, M. C.
Right arrow Articles by Berkovic, S. F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2005). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Mutation in the Na+ channel subunit SCN1B produces paradoxical changes in peripheral nerve excitability

Matthew C. Kiernan1,2, Arun V. Krishnan1,2, Cindy S.-Y. Lin1,3, David Burke3 and Samuel F. Berkovic4

1 Prince of Wales Medical Research Institute and Prince of Wales Clinical School, University of New South Wales, 2 Department of Neurology, Prince of Wales Hospital, 3 Institute of Clinical Neurosciences, University of Sydney and Royal Prince Alfred Hospital, Sydney and 4 Epilepsy Research Centre, University of Melbourne, Austin Health, Victoria, Australia

Correspondence to: Dr Matthew C. Kiernan, Prince of Wales Medical Research Institute, Barker Street, Randwick, Sydney, NSW 2031, Australia E-mail: M.Kiernan{at}unsw.edu.au

To determine the effect of an established mutation of the ß1 subunit of Na+ channels on nerve excitability, studies were undertaken in patients diagnosed with generalized epilepsy with febrile seizures plus (GEFS+). Multiple nerve excitability measurements were used to investigate the membrane properties of sensory and motor axons in five patients (aged 18–55 years) who were currently experiencing no seizures and were not on anticonvulsants. There was no history of paraesthesiae, fasciculation or cramps to suggest hyperexcitability of peripheral nerve axons. The median nerve was stimulated at the wrist, and compound muscle action potentials (CMAPs) were recorded from abductor pollicis brevis and the antidromic compound sensory nerve action potential (CSAPs) from digit 2. Stimulus–response behaviour, strength–duration time constant, threshold electrotonus, current–threshold relationship and the recovery of excitability following a supramaximal conditioning stimulus were recorded using threshold tracking. Compared with normal controls (n = 29), the axons of patients were of higher threshold. CMAPs and CSAPs were relatively small, although individual values remained within the normal ranges. Refractoriness and relative refractory period (markers of transient Na+ channel function) were significantly reduced in GEFS+ patients with established mutations in SCN1B (P < 0.05), and strength–duration time constants (dependent on persistent Na+ conductances) were reduced. It is suggested that, in peripheral nerve axons, the mutation underlying GEFS+ reduces the number of functioning Na+ channels at the node of Ranvier and that this rather than any change in gating of individual channels dominates axonal excitability in these patients.

Key Words: Na+ channel; SCN1B; epilepsy; axonal excitability

Abbreviations: CMAP = compound muscle action potential; CSAP = compound sensory nerve action potential; GEFS+ = generalized epilepsy with febrile seizures plus; RRP = relative refractory period

Received February 4, 2005. Revised March 21, 2005. Accepted April 1, 2005.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
BrainHome page
S. B. Park, C. S.-Y. Lin, A. V. Krishnan, D. Goldstein, M. L. Friedlander, and M. C. Kiernan
Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy
Brain, October 1, 2009; 132(10): 2712 - 2723.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. B. Park, D. Goldstein, C. S.-Y. Lin, A. V. Krishnan, M. L. Friedlander, and M. C. Kiernan
Acute Abnormalities of Sensory Nerve Function Associated With Oxaliplatin-Induced Neurotoxicity
J. Clin. Oncol., March 10, 2009; 27(8): 1243 - 1249.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
C. S.-Y. Lin, A. V. Krishnan, M.-J. Lee, A. S. Zagami, H.-L. You, C.-C. Yang, H. Bostock, and M. C. Kiernan
Nerve function and dysfunction in acute intermittent porphyria
Brain, September 1, 2008; 131(9): 2510 - 2519.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. V. Krishnan, D. Goldstein, M. Friedlander, and M. C. Kiernan
Oxaliplatin and Axonal Na+ Channel Function In vivo
Clin. Cancer Res., August 1, 2006; 12(15): 4481 - 4484.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.